Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer
Status:
Completed
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This study is to examine the anticancer activity of the combination therapy with all-trans
retinoic acid and nivolumab in patients with chemotherapy-refractory advanced or metastatic
pancreatic adenocarcinoma.